Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort - Report - MDSpire
Advertisement
Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort
Clinical and Histological Factors Linked to Type 1 Gastric Neuroendocrine Tumors
Overview
This study evaluates the occurrence of type I gastric neuroendocrine tumors (T1gNETs) in patients with autoimmune atrophic gastritis (AIG) and identifies associated clinical, biochemical, and histological factors. ECL cell hyperplasia was found to be the strongest histological factor linked to T1gNETs, while dyspeptic symptoms showed an inverse correlation with tumor occurrence.
Background
Autoimmune gastritis (AIG) is a chronic inflammatory condition that increases the risk of developing T1gNETs. Understanding the clinical and histological factors associated with T1gNETs is crucial for risk stratification and surveillance in AIG patients.
Data Highlights
Factor
Association with T1gNETs
P-value
ECL cell hyperplasia
82.1% vs 55.8%
0.0109
Dyspeptic symptoms
21.4% vs 43.5%
0.035
Key Findings
16% of AIG patients were diagnosed with T1gNETs.
ECL cell hyperplasia was significantly associated with T1gNETs (p=0.0109).
Dyspeptic symptoms inversely correlated with T1gNET occurrence (p=0.035).
No significant predictive value was found for smoking, alcohol, BMI, or severe hypergastrinemia/CgA levels.
A trend was observed for corpus metaplasia as a potential risk factor.
Clinical Implications
The findings indicate that AIG patients with ECL cell hyperplasia may have an increased risk for T1gNETs.
Conclusion
The study identifies key clinical and histological factors associated with T1gNETs in AIG patients.
by Roberta Elisa Rossi, Matteo Ferraris, Lorenzo Petronio, Benedetta Masoni, Luca Di Stefano, Alexia Francesca Bertuzzi, Sara Fraticelli, Andrea Gerardo Antonio Lania, Alessandro Zerbi, Cesare Hassan, Alessandro Repici
